G1 Therapeutics Inc. (NASDAQ:GTHX) Q4 2022 Earnings Conference Call March 1, 2023 8:30 AM ET
Company Participants
Jack Bailey - Chief Executive Officer
Jennifer Moses - Chief Financial Officer
Raj Malik - Chief Medical Officer
Andrew Perry - Chief Commercial Officer
Will Roberts - Vice President, Communications
Conference Call Participants
Gil Blum - Needham & Co.
Joseph Thome - Cowen & Co.
Dane Leone - Raymond James
Priyanka Grover - JP Morgan
Operator
Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call.
At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star-one-one on your telephone. You will then hear an automated message advising that your hand has been raised. To withdraw your question, please press star-one-one again. Please be advised that today’s conference is being recorded.
It is now my pleasure to introduce Vice President of Communications, Will Roberts.
Will Roberts
Thank you Andrew. Good morning everyone and welcome to the G1 conference call to discuss our fourth quarter and full year 2022 financial results and business update. The press release on these financial results was issued this morning and can be found in the News section of our corporate website, g1therapeutics.com.
On this morning’s call, the team will provide a business overview of the fourth quarter of 2022, including an update on our clinical programs and our commercial progress in that period with Cosela, which is approved and commercial available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen, or topotecan-containing regimens for extensive-stage small cell lung cancer. A Q&A session will follow the prepared remarks.
Before we begin, I’d like to remind you that today’s webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management’s judgment as of today and may involve risks and uncertainties that could actual results to differ materially from those expressed in or implied by these statements. For more information on such risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, March 1, 2023.
Joining me on the call today are Jack Bailey, our Chief Executive Officer; Raj Malik, our Chief Medical Officer; Andrew Perry, our Chief Commercial Officer; and Jen Moses, our Chief Financial Officer.